The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 748K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

17 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
3,4-dihydro-2(1H)-quinolinone as a novel antidepressant drug: synthesis and pharmacology of 1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-3,4- dihydro-5-methoxy-2(1H)-quinolinone and its derivatives.EBI
Otsuka Pharmaceutical
Characterization of orally active nonpeptide vasopressin V(2) receptor agonist. Synthesis and biological evaluation of both the (5R)- and (5S)-enantioisomers of 2-[1-(2-Chloro-4-pyrrolidin-1-yl-benzoyl)-2,3,4,5-tetrahydro-1H-1-benzazepin- 5-yl]-N-isopropylacetamide.EBI
Otsuka Pharmaceutical
Novel design of nonpeptide AVP V(2) receptor agonists: structural requirements for an agonist having 1-(4-aminobenzoyl)-2,3,4, 5-tetrahydro-1H-1-benzazepine as a template.EBI
Otsuka Pharmaceutical
Orally active, nonpeptide vasopressin V2 receptor antagonists: a novel series of 1-[4-(benzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepines and related compounds.EBI
Otsuka Pharmaceutical
Orally active, nonpeptide vasopressin V1 antagonists. A novel series of 1-(1-substituted 4-piperidyl)-3,4-dihdyro-2(1H)-quinolinone.EBI
Otsuka Pharmaceutical
5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2 Pyridyl]Amino]Pyrazine-2-carbonitrile and therapeutic uses thereofBDB
Cancer Research Technology
Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitorsBDB
Biocryst Pharmaceuticals
Heterocyclic compounds for the inhibition of PASKBDB
Bioenergenix
PARG inhibitory compoundsBDB
Cancer Research Technology
Methods, compositions, and uses of novel Fyn kinase inhibitorsBDB
Pathways Neuro Pharma
Negative allosteric modulators of metabotropic glutamate receptor 3BDB
Vanderbilt University
Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]OXAZEPINES and methods for treating viral infectionsBDB
Gilead Sciences
Partially saturated nitrogen-containing heterocyclic compoundBDB
Taisho Pharmaceutical
The discovery of novel β-secretase inhibitors: pharmacophore modeling, virtual screening, and docking studies.BDB
Peking University Health Science Center
The interaction of the enantiomers of aceclidine with subtypes of the muscarinic receptor.BDB
University of California